Kymera Therapeutics is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s initial programs are IRAK4, IRAKIMiD, and STAT3, each of which addresses high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.
Kymera Therapeutics
TAP Partner
Watertown, Massachusetts
United States
Project Title
A phase 1 study of KT-413, a dual degrader of IRAK4 and IMiD substrates, in patients with DLBCL A phase 1 study of KT-333, a STAT3 protein degrader, in patients with NHL
Program
Therapy Acceleration Program